Detalle Publicación


Appraisal of triglyceride-related markers as early predictors of metabolic outcomes in the PREVIEW Lifestyle Intervention: A controlled post-hoc trial

Autores: Navas Carretero, Santiago (Autor de correspondencia); San Cristóbal Blanco, Rodrigo (Autor de correspondencia); Vestentoft, P. S.; Brand-Miller, J. C.; Jalo, E.; Westerterp-Plantenga, M.; Simpson, E. J.; Handjieva-Darlenska, T.; Stratton, G.; Huttunen-Lenz, M.; Lam, T.; Muirhead, R.; Poppitt, S.; Pietilainen, K. H.; Adam, T.; Taylor, M. A.; Handjiev, S.; McNarry, M. A.; Hansen, S.; Brodie, S.; Silvestre, M. P.; Macdonald, I. A.; Boyadjieva, N.; Mackintosh, K. A.; Schlicht, W.; Liu, A.; Larsen, T. M.; Fogelholm, M.; Raben, A.; Martínez Hernández, Alfredo
Título de la revista: FRONTIERS IN NUTRITION
ISSN: 2296-861X
Volumen: 8
Páginas: 733697
Fecha de publicación: 2021
Background Atrial fibrillation (AF) increases the risk of thromboembolism. We investigate the efficacy and safety of oral anticoagulation (OAC) therapy and explored the number needed to treat for net effect (NNTnet) of OAC in the Spanish cohort of the EURObservational Research Programme-AF (EORP-AF) Long-term General Registry. Methods The EORP-AF General Registry is a prospective, multicentre registry conducted in ESC countries, including consecutive AF patients. For the present analysis, we used the Spanish cohort, and the primary outcome was any thromboembolism (TE)/acute coronary syndrome (ACS)/cardiovascular death during the first year of follow-up. Results 729 AF patients were included (57.1% male, median age 75 [IQR 67-81] years, median CHA(2)DS(2)-VASc and HAS-BLED of 3 [IQR 2-5] and 2 [IQR 1-2], respectively). 548 (75.2%) patients received OAC alone (318 [43.6%] on VKAs and 230 [31.6%] on DOACs). After 1 year, the use of OAC alone showed lower rates of any TE/ACS/cardiovascular death (3.0%/year; p < 0.001) compared to other regimens, and non-use of OAC alone (HR 4.18, 95% CI 2.12-8.27) was independently associated with any TE/ACS/cardiovascular death. Balancing the effects of treatment, the NNTnet to provide an overall benefit of OAC therapy was 24. The proportion of patients on OAC increased at 1 year (87% to 88.1%), particularly on DOACs (33.6% to 39.9%) (p = 0.015), with low discontinuation rates. Conclusions In this contemporary cohort of AF patients, OAC therapy was associated with better clinical outcomes at 1 year and positive NNTnet. OAC use slightly increased during the follow-up, with low discontinuation rates and higher prescription of DOACs.